Following these developments, it has become increasingly important to determine the receptor subtype of the tumor in guiding systemic treatment choices, even in second- and further-line settings due to the potential changes in HR and HER2 expression between primary tumor and metastatic sites, or before and after a first- or second-line treatment. The gene discussed is ERBB2; the disease is neoplasm.